Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.

By J. Bendell, J. Rodón, H. Burris, M. D. de Jonge, J. Verweij, D. Birle, D. Demanse, S. D. De Buck, Q. Ru, M. Peters and 2 more. Journal of Clinical Oncology, 2012

665 citations recorded by the source corpus.

Subfields: Genetics, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/84f79dfa5007811effc9725a0987f441d221334b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Carlos L. Arteaga
2. R. Abraham
3. D. Fruman

In Molecular Biology

1. D. Fruman
2. Carlos L. Arteaga
3. B. Hopkins
4. Ingrid A. Mayer
5. R. Abraham
6. Honyin Chiu
7. S. Bagrodia
8. Lewis C. Cantley

Citations in the corpus

• The PI3K pathway in human disease (2017, background): “The BELLE series of clinical trials assessed the efficacy and safety of various drug combinations with the pan-PI3K inhibitor buparlisib (BKM120; Table S1) in patients with ER+, HER2– breast cancer.”
• The PI3K/AKT Pathway as a Target for Cancer Treatment. (2016, background): “These side effects were generally mild and responsive to dose reductions or interruptions (suggestive of dose dependence), as well as treatment with selective serotonin reuptake inhibitors and anxiolytics (42, 49).”
• Targeting PI3K/Akt signal transduction for cancer therapy (2021, background): “5–150mg per day, the administration of BKM120 at the maximum tolerated dose of 100mg/day was safe and exhibited preliminary antitumor activity.(200) Another class I inhibitor, XL147, has high specificity for four subtypes of PI3Ks.”